Shareholder Alert: The Ademi Firm investigates whether Penumbra, Inc. is obtaining a Fair Price for its Public Shareholders

Core Viewpoint - Ademi LLP is investigating Penumbra for potential breaches of fiduciary duty and other legal violations related to its transaction with Boston Scientific [1] Group 1: Transaction Details - Penumbra stockholders can choose to receive either $374 in cash or 3.8721 shares of Boston Scientific common stock per share, with the total transaction consideration being approximately 73% in cash and 27% in stock [2] - Penumbra insiders are set to receive significant benefits as part of the change of control arrangements [2] Group 2: Board Conduct and Limitations - The transaction agreement imposes significant penalties on Penumbra for accepting competing bids, which may limit the board's ability to consider other offers [3] - The investigation focuses on whether the Penumbra board is fulfilling its fiduciary duties to all shareholders amid these limitations [3]